Drug reference

Aclidinium

Antimuscarinic · Airways disease, obstructive

Also known as Aclidinium bromide

AntimuscarinicAirways disease, obstructive

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Manufacturer advises use only if potential beneﬁt outweighs risk.

FDA category + note

Mechanism

Aclidinium is an antimuscarinic agent, functioning as a synthetic analog of atropine. It acts by antagonizing muscarinic receptors, particularly M3 receptors in the airways, to inhibit the vagally-mediated bronchoconstrictor reflex. This blockade leads to bronchodilation, which is beneficial in patients with chronic obstructive pulmonary disease (COPD).

Indications

Maintenance treatment of chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease (COPD)

Dosing

Adult: 375 micrograms twice daily by inhalation of powder
Geriatric: Prescription potentially inappropriate (STOPP criteria) with a history of narrow-angle glaucoma (may exacerbate glaucoma) or bladder outﬂow obstruction (may cause urinary retention).

Pharmacokinetics

Metabolism

Rapid hydrolysis in plasma to inactive metabolites

Contraindications

Arrhythmia (when newly diagnosed within last 3 months)
Heart failure (hospitalisation with moderate or severe heart failure within last 12 months)
Myocardial infarction within last 6 months
Unstable angina
Bladder outﬂow obstruction
Paradoxical bronchospasm
Prostatic hyperplasia
Susceptibility to angle-closure glaucoma
History of narrow-angle glaucoma